Bonk (SHOT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Oct, 2026Executive summary
Virtual annual meeting scheduled for December 11, 2026; the Board recommends voting FOR all three proposals: six director nominees, auditor ratification, and an equity-plan share increase.
October 14, 2026 record-date voting power: 7,943,083 common votes and 7,020,000 Series C preferred votes.
Voting matters and shareholder proposals
Proposal 1 seeks re-election of six directors through the 2027 annual meeting; each nominee requires a majority of shares present or represented and entitled to vote.
Proposal 2 seeks ratification of M & K CPAS, PLLC for FY 2026; Proposal 3 seeks to raise the 2024 Plan reserve by 742,857 shares, from 1,057,143 to 1,800,000.
Abstentions count toward quorum and have the same effect as votes against; broker non-votes do not affect proposal outcomes.
Board of directors and corporate governance
Six nominees: Jarrett Boon, Christopher Marc Melton, Mitchell Rudy, Connor Klein, James McAvity, and Stacey Duffy; four nominees meet Nasdaq independence standards.
Board held 5 meetings in FY 2025; all directors attended at least 90% of Board and committee meetings for which they served.
Board separates CEO and chair roles; independent director Christopher Melton became chair in April 2026, while the Board retains discretion to combine the roles later.
Standing Audit, Compensation, and Nominating and Corporate Governance committees have written charters and intend annual reviews of their charters and practices.
Latest events from Bonk
- Three proposals seek director re-election, auditor ratification, and a larger equity-plan reserve.SHOT
Proxy filing - Revenue surged to $5.5M, but a $7.9M net loss and going concern doubts persist.SHOT
Q2 2026 - Revenue surged in Q1 2026, but liquidity and regulatory risks remain significant.SHOT
Q1 2026 - Shelf registration enables up to $100M in securities sales as company pivots to digital assets.SHOT
Registration filing - 2025 revenue grew to $3.93M, but net loss deepened to $68.2M amid digital asset volatility.SHOT
Q4 2025 - Amended registration for public stock offering, led by CEO Jarrett Boon, with $113K in expenses.SHOT
Registration Filing - Patented dietary supplement business registers shares for resale, funding R&D and growth.SHOT
Registration Filing - Registering 1.9M shares for resale; proceeds from warrants fund R&D and working capital.SHOT
Registration Filing - Patented dietary supplement targets alcohol metabolism, with shares registered for resale on NASDAQ.SHOT
Registration Filing